Table 1.
Baseline characteristics
| Baseline characteristics | Placebo (n = 8) | Dapagliflozin 10 mg (n = 8) | P value |
|---|---|---|---|
| Male sex, N (%) | 5 (62.5) | 8 (100) | |
| Age, years | 67 ± 2.2 | 66 ± 2.6 | P = 0.7 |
| Diabetes duration, years | 8.25 ± 0.6 | 6.3 ± 1.0 | P = 0.2 |
| HbAlc, % | 8.1 ± 0.2 | 7.8 ± 0.1 | P = 0.45 |
| Fasting glycemia (mg/dl) | 136 ± 17 | 140 ± 12 | P = 0.5 |
| C-peptide (ng/ml) | 1.4 ± 0.3 | 1.7 ± 0.2 | P = 0.6 |
| BMI, kg/m2 | 28.5 ± 1.0 | 27.3 ± 1.1 | P = 0.3 |
| Body weight, kg | 81.8 ± 4.7 | 81.8 ± 2.6 | P > 0.9 |
| Heart rate, bpm | 61 ± 4 | 65 ± 4 | P = 0.9 |
| Systolic BP, mmHg | 135 ± 5.2 | 143 ± 5.1 | P = 0.2 |
| Diastolic BP, mmHg | 71 ± 3.8 | 68 ± 4.4 | P = 0.4 |
| CAD (previous PCl/no PCI) | 4/4 | 3/5 | P = 0.3 |
| eGFR (ml/min) | 90.6 ± 3.1 | 85.8 ± 6.2 | P = 0.5 |
| Medications | |||
| Metformin | 8 (100) | 7 (87.5) | |
| DPP- 4i | 4 (50) | 3 (37.5) | |
| GLP-1RA | 2 (25) | 1 (12.5) | |
| Basal insulin | 2 (25) | 3 (37.5) | |
| Sulfonylurea | 2 (25) | 1(12.5) |
Data are mean ± SEM. HbA1c, glycated hemoglobin; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate